TARS (Tarsus Pharmaceuticals) Ending Cash Position: $104.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TARS Tarsus Pharmaceuticals Inc TARS
47 GF Score
Price $56.23
GF Value $205.81
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Tarsus Pharmaceuticals Ending Cash Position?

Tarsus Pharmaceuticals TARS -5.15% 47 Ending Cash Position is $104.2 Mil as of Mar. 2026. GuruFocus rates TARS with a GF Score™ of 47/100 and a GF Value™ of $205.81 (Possible Value Trap). The stock has 2 warning signs investors should review.

Tarsus Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 was $104.2 Mil.

Tarsus Pharmaceuticals's quarterly Ending Cash Position increased from Sep. 2025 ($115.3 Mil) to Dec. 2025 ($186.2 Mil) but then declined from Dec. 2025 ($186.2 Mil) to Mar. 2026 ($104.2 Mil).

Tarsus Pharmaceuticals's annual Ending Cash Position declined from Dec. 2023 ($224.9 Mil) to Dec. 2024 ($97.4 Mil) but then increased from Dec. 2024 ($97.4 Mil) to Dec. 2025 ($186.2 Mil).

Tarsus Pharmaceuticals Ending Cash Position Related Terms

Tarsus Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Tarsus Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsus Pharmaceuticals Ending Cash Position Chart

Tarsus Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 171.33 71.66 224.95 97.38 186.20

Tarsus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 178.35 99.21 115.29 186.20 104.19
TARS
47GF Score
Tarsus Pharmaceuticals Inc TARS
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tarsus Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Tarsus Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=97.381+88.822
=186.2

Tarsus Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=186.203+-82.01
=104.2

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $104.2 Mil mean?
Tarsus Pharmaceuticals (TARS) has a Ending Cash Position of $104.2 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Tarsus Pharmaceuticals and its competitors.
Is Tarsus Pharmaceuticals' Ending Cash Position too high?
Tarsus Pharmaceuticals' current Ending Cash Position is $104.2 Mil. Overall, Tarsus Pharmaceuticals has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Ending Cash Position compare to KLRA and CLDX?
Tarsus Pharmaceuticals' Ending Cash Position of $104.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Tarsus Pharmaceuticals and its competitors. Tarsus Pharmaceuticals's current Ending Cash Position is $104.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Possible Value Trap. The stock's GF Value™ is $205.81, compared to a current price of $56.23 — trading 72.7% below its estimated fair value. The current Ending Cash Position is $104.2 Mil. Tarsus Pharmaceuticals' overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Ending Cash Position is $104.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?

Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued. The current stock price of $56.23 is trading 72.7% below its estimated GF Value™ of $205.81. GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TARS:

  • Ending Cash Position: $104.2 Mil
  • GF Value™: $205.81 vs. price of $56.23 (72.7% below fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tarsus Pharmaceuticals Business Description

Address 15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
47GF Score

Get the complete analysis for TARS

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$56.23
Price
$205.81
GF Value